BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 1328977)

  • 1. Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease.
    Schink JC; Singh DK; Rademaker AW; Miller DS; Lurain JR
    Obstet Gynecol; 1992 Nov; 80(5):817-20. PubMed ID: 1328977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease.
    Soper JT; Evans AC; Clarke-Pearson DL; Berchuck A; Rodriguez G; Hammond CB
    Obstet Gynecol; 1994 Jan; 83(1):113-7. PubMed ID: 8272290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors.
    Matsui H; Suzuka K; Iitsuka Y; Seki K; Sekiya S
    Gynecol Oncol; 2000 Jul; 78(1):28-31. PubMed ID: 10873405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary chemotherapy for high-risk gestational trophoblastic neoplasia.
    Lurain JR; Nejad B
    Gynecol Oncol; 2005 May; 97(2):618-23. PubMed ID: 15863169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methotrexate monotherapy for high-risk gestational trophoblastic neoplasia after therapy with etoposide, methotrexate, and dactinomycin: a case report.
    Taran A; Ignatov A; Smith B; Bischoff J; Costa SD
    Am J Obstet Gynecol; 2008 Nov; 199(5):e6-8. PubMed ID: 18984073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage combination chemotherapy with 5-fluorouracil and actinomycin D for patients with refractory, high-risk gestational trophoblastic tumors.
    Matsui H; Suzuka K; Iitsuka Y; Yamazawa K; Tanaka N; Mitsuhashi A; Seki K; Sekiya S
    Cancer; 2002 Sep; 95(5):1051-4. PubMed ID: 12209690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease.
    Dobson LS; Lorigan PC; Coleman RE; Hancock BW
    Br J Cancer; 2000 May; 82(9):1547-52. PubMed ID: 10789722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-risk metastatic gestational trophoblastic tumors. Current management.
    Lurain JR
    J Reprod Med; 1994 Mar; 39(3):217-22. PubMed ID: 7518518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary treatment of metastatic high-risk gestational trophoblastic neoplasia with EMA-CO chemotherapy.
    Lurain JR; Singh DK; Schink JC
    J Reprod Med; 2006 Oct; 51(10):767-72. PubMed ID: 17086804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placental site trophoblastic tumor: an overview.
    Bonazzi C; Urso M; Dell'Anna T; Sacco S; Buda A; CantĂș MG
    J Reprod Med; 2004 Aug; 49(8):585-8. PubMed ID: 15457847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma methotrexate levels in patients receiving etoposide, methotrexate, actinomycin, cyclophosphamide, and vincristine (EMA-CO) chemotherapy for trophoblastic neoplasia.
    Kohorn EI
    Gynecol Oncol; 1993 Sep; 50(3):300-4. PubMed ID: 8406191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors.
    Newlands ES; Mulholland PJ; Holden L; Seckl MJ; Rustin GJ
    J Clin Oncol; 2000 Feb; 18(4):854-9. PubMed ID: 10673528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of high-risk gestational trophoblastic disease with methotrexate, actinomycin D, and cyclophosphamide chemotherapy.
    Lurain JR; Brewer JI
    Obstet Gynecol; 1985 Jun; 65(6):830-6. PubMed ID: 2987766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination chemotherapy with 5-fluorouracil, methotrexate and etoposide for patients with high-risk gestational trophoblastic tumors: a report based on our 11-year clinical experiences.
    Wang S; An R; Han X; Zhu K; Xue Y
    Gynecol Oncol; 2006 Dec; 103(3):1105-8. PubMed ID: 16870237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-risk metastatic gestational trophoblastic disease. A new dose-intensive, multiagent chemotherapeutic regimen.
    Surwit EA; Childers JM
    J Reprod Med; 1991 Jan; 36(1):45-8. PubMed ID: 1848900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel strategy using G-CSF to support EMA/CO for high-risk gestational trophoblastic disease.
    Hartenbach EM; Saltzman AK; Carter JR; Twiggs LB
    Gynecol Oncol; 1995 Jan; 56(1):105-8. PubMed ID: 7529741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine chemotherapy.
    Cyriac S; Rajendranath R; Sridevi V; Sagar TG
    J Reprod Med; 2011; 56(5-6):219-23. PubMed ID: 21682117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of drug resistant gestational trophoblastic neoplasia.
    Patel SM; Desai A
    J Reprod Med; 2010; 55(7-8):296-300. PubMed ID: 20795341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of high-risk gestational trophoblastic disease.
    Surwit EA
    J Reprod Med; 1987 Sep; 32(9):657-62. PubMed ID: 2822919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of high-risk gestational trophoblastic disease.
    Lurain JR
    J Reprod Med; 1998 Jan; 43(1):44-52. PubMed ID: 9475149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.